DuPont Human Microbiome Venture and Procter & Gamble Enter Research Collaboration in Next Generation Probiotics

TipRanks

Goldman Sachs: These 3 Stocks Are Poised to Surge by at Least 50%

Is it time for the bears to break out the champagne glasses? Not so fast, says Goldman Sachs. Volatility has ruled the Street for the last few weeks, leading some to conclude that those with a more pessimistic outlook had been vindicated, but the firm believes stocks can still climb higher.According to Goldman Sachs’ head of U.S. equity strategy, David Kostin, the S&P 500 could still hit 3,600 by the end of the year, and 3,800 by mid-2021, on the back of vaccine-related optimism and progress with the economic reopening. This would reflect gains of 10% and 16%, respectively, should the index ultimately reach these targets.“Despite the sharp sell-off in the past week, we remain optimistic about the path of the U.S. equity market in coming months. The Superforecaster probability of a mass-distributed vaccine by Q1

Read More

3CL Protease Inhibitor NLC-001 Added to COVID-19-focused Joint Venture Between Todos Medical and NLC Pharma

  •  NLC-001 is a proprietary blend of plant extracts administered orally as dietary supplement
  •  US FDA granted Certificate of Free Sale for NLC-001 on August 28, 2020
  •  JV evaluating potential of NLC-001 to treat COVID-19 in clinical studies in Israel
  •  Todos evaluating commercialization options for NLC-001 Worldwide

NEW YORK, REHOVOT, Israel and SINGAPORE, Sept. 17, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on developing and distributing comprehensive solutions for COVID-19, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced that NLC Pharma has added the dietary supplement NLC-001 to its joint venture with Todos Medical. NLC-001 is an orally administered proprietary blend of plant extracts that includes a powerful potential 3CL protease inhibitor that could help support and maintain healthy immune function. The 3CL protease plays a vital role in the intracellular replication

Read More

Robots Driving Forklifts Score Venture Capital, Create Jobs

(Bloomberg) — Silicon Valley investors are increasing bets on a Pittsburgh company that turns a venerable machine of the past century of industrialization — the forklift — into a driver of the e-commerce boom.

Loading...

Load Error

Seegrid Corp., a maker of autonomous forklifts and robot-powered vehicles used to move materials around warehouses and factories, just closed on equity financing totaling $52 million from Menlo, California-based venture fund G2VP LLC and an undisclosed group of tech and robotics investors.

The deal, with UBS Group AG serving as an adviser, brought to $150 million the total amount of funding received by Seegrid, which has a valuation of more than $400 million.

The fresh round of financing during a pandemic underscores the rising demand to shore up supply chains increasingly dependent on warehouses and distribution hubs as consumer dabbling with online shopping turns more habitual. Seegrid expects to double revenue this year and

Read More